Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Locally Advanced Urothelial Carcinoma: early-phase trial registry
3 of 15 indexed Locally Advanced Urothelial Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 3 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Locally Advanced Urothelial Carcinoma: 15 US clinical trials tracked, 3 recruiting.
Locally Advanced Urothelial Carcinoma is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 5 of these trials.
Enrollment posture brief
Registry condition locally-advanced-urothelial-carcinoma
OPEN 3 | RECR 20% | LATE 3 | EARLY 12 | RANK #1140 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)
Locally Advanced Urothelial Carcinoma lists 3 open slots (20% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Locally Advanced Urothelial Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Locally Advanced Urothelial Carcinoma is recruiting below its size-band peers.
3 of 15 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Locally Advanced Urothelial Carcinoma research.
National Cancer Institute (NCI) accounts for 5 of 15 trials (33.3%). 10 distinct sponsors appear on at least one study for this condition label.
-
Most Locally Advanced Urothelial Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 32 among the 15 trials that report a genuine target (sentinel values excluded). 11 of those (73.3%) plan for fewer than 100 participants.
-
Locally Advanced Urothelial Carcinoma research is mostly interventional.
15 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
National Cancer Institute (NCI)
NCT06524544
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Emory University
NCT04878029
Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma
Yale University
NCT07048457
Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer
National Cancer Institute (NCI)
NCT03244384
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
Tyra Biosciences
NCT05544552
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
National Cancer Institute (NCI)
NCT00365157
Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
Fox Chase Cancer Center
NCT05923190
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
Merck Sharp & Dohme
NCT06483334
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
Mayo Clinic
NCT04007744
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
National Cancer Institute (NCI)
NCT03854474
Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy
National Cancer Institute (NCI)
NCT04963153
Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma
University of Utah
NCT05154994
ARID1A and/or KDM6A Mutation and CXCL13 Expression
M.D. Anderson Cancer Center
NCT04953104
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
Emory University
NCT04848519
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
Alliance for Clinical Trials in Oncology
NCT04637594
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 4 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Locally Advanced Urothelial Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Locally Advanced Urothelial Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Locally Advanced Urothelial Carcinoma page
15 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Locally Advanced Urothelial Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Locally Advanced Urothelial Carcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Locally Advanced Urothelial Carcinoma condition card totals 15 registered trials; most-linked intervention Computed Tomography; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.